Pacira BioSciences Reports Receipt of Director Nominations from DOMA Perpetual

Pacira Biosciences Confirms Receipt of Director Nominations from Doma Perpetual

VALHALLA, N.J., March 25, 2023 /PRNewswire/ -- Pacira Biosciences Inc. (NASDAQ: PCRX), a leading provider of innovative surgical instruments and implants, today confirmed receipt of director nominations from Doma Perpetual LLC.

As per the filing with the Securities and Exchange Commission (SEC), Doma Perpetual LLC has nominated two individuals, Dr. Lisa M. Baugh and Dr. David A. Kessler, for election to the Pacira Biosciences board of directors.

Pacira Biosciences has accepted the nominations and will include the nominees in its proxy statement for the upcoming annual meeting of shareholders. The company will provide additional information regarding the nominees and the election process in the coming days.

Pacira Biosciences is a leading provider of innovative surgical instruments and implants. The company's products are designed to improve patient outcomes, reduce healthcare costs, and increase the efficiency of surgical procedures. Pacira Biosciences' portfolio includes EXPAREL, a local anesthetic indicated for use in surgical procedures, and other products that address unmet needs in the surgical marketplace.

About Pacira Biosciences

Pacira Biosciences is a leading provider of innovative surgical instruments and implants. The company's products are designed to improve patient outcomes, reduce healthcare costs, and increase the efficiency of surgical procedures. Pacira Biosciences' portfolio includes EXPAREL, a local anesthetic indicated for use in surgical procedures, and other products that address unmet needs in the surgical marketplace. For more information, visit Pacira Biosciences' website at www.pacira.com.